<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
  <channel>
    <title>CancerCompass Message Board: Successful new treatment</title>
    <description>CancerCompass message board discussion started by Tagml on 2/29/2008</description>
    <link>http://www.cancercompass.com/message-board/message/all,21506,0.htm</link>
    <pubDate>Fri, 05 Dec 2008 00:00:00 GMT</pubDate>
    <lastBuildDate>Fri, 05 Dec 2008 00:00:00 GMT</lastBuildDate>
    <docs>http://backend.userland.com/rss</docs>
    <generator>RSS.NET: http://www.rssdotnet.com/</generator>
    <item>
      <title>Successful new treatment</title>
      <description>From another board, this is a great piece of news for those who have advance RCC and had trouble with Sutent, Nexavar, or Torisel. I have been trying to get it on the board but am having some computer troupble so sorry if it is a repeat...&amp;nbsp;For those like me who have a time of keeping all this straight Everolimus is aka RAD-001 Everolimus is approved under the trade-name Certican&amp;reg; for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003 and is available in more than 60 countries. More: http://tinyurl.com/342sao  Best, Bill Bro, CEO, www.kidneycancer.org </description>
      <author>Tagml</author>
      <pubDate>Fri, 29 Feb 2008 00:00:00 GMT</pubDate>
    </item>
  </channel>
</rss>